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Serum (133)--D-glucan concentrations were serially measured in the presence and absence of antifungal
therapy in a murine model of invasive pulmonary aspergillosis. Serum (133)--D-glucan was detected early
during the course of infection, and reductions in this biomarker were associated with improved survival in
animals treated with antifungal agents.
Early diagnosis and initiation of antifungal therapy have
been demonstrated to improve outcomes in invasive aspergil-
losis (2, 3). Serial screening of serum for galactomannan and
computed tomography have been shown to result in the earlier
initiation of antifungal therapy in patients with invasive as-
pergillosis while avoiding unnecessary empirical antifungal use
(4). However, the sensitivity of galactomannan is reduced in
patients receiving antifungal agents (5). An assay for serum
(133)--D-glucan is available and has been shown to be a
useful diagnostic marker for invasive fungal infections (6, 7).
However, there are few data for this assay regarding the diag-
nosis of invasive aspergillosis and its performance in the setting
of drug therapy.
(This work was presented in part at the 47th Interscience
Conference on Antimicrobial Agents and Chemotherapy, Chi-
cago, IL, 17 to 20 September 2007.)
The objectives of our study were to measure the serum
concentrations of (133)--D-glucan over time following pul-
monary inoculation of an animal model of invasive pulmonary
aspergillosis and to examine the utility of this assay as a bio-
marker of disease burden in the presence of antifungal ther-
apy. To achieve these objectives, outbred ICR mice (Harlan),
weighing between 18 and 22 g, were immunosuppressed by
cortisone acetate and cyclophosphamide and inoculated via an
inhalation chamber on day 0 with either Aspergillus fumigatus
clinical isolate AF 293 or CEA 10 as previously described (8).
To assess changes in serum (133)--D-glucan concentrations
over time, mice were randomly chosen on days 1, 3, 5, and 7
postinoculation and euthanized, and blood samples were col-
lected by cardiac puncture. The effects of antifungal therapy on
serum (133)--D-glucan concentrations were measured in
mice randomly assigned to one of four treatment regimens
beginning 1 day after inoculation: (i) control, (ii) 3 mg/kg
amphotericin B deoxycholate intraperitoneally once a day
(QD), (iii) 40 mg/kg posaconazole orally QD, or (iv) 10 mg/kg
liposomal amphotericin B intravenously QD. In the survival
arm, therapy was continued until day 7 postinoculation, and
animals were monitored off therapy until day 12. For fungal
burden, therapy was continued until day 4. Mice were eutha-
nized on day 5, and blood and lung samples were collected.
Serum (133)--D-glucan concentrations were measured using
a commercially available kit (Fungitell, Associates of Cape
Cod). Five microliters of each sample was transferred in du-
plicate to a 96-well cell culture tray and processed according to
the manufacturer’s instructions [package insert, Fungitell assay
for (1,3)--D-glucan in serum; Associates of Cape Cod, East
Falmouth, MA]. The mean rate of change at an optical density
of 405 nm for each sample was read over 40 min with a mi-
croplate spectrophotometer (Synergy HT; Biotek Instruments,
Inc., Winooski, VT), and unknowns were interpolated from a
standard curve. To measure the pulmonary fungal burden,
lungs were homogenized in sterile saline and DNA was ex-
tracted using a commercially available kit (QIAamp DNA mini
kit; Qiagen, Valencia, CA). Fungal DNA was measured by a
real-time PCR assay using a probe and primers specific for the
A. fumigatus FKS gene (GenBank accession no. U79728) and
reported as conidial equivalents per gram of lung tissue (9).
Each study was conducted in duplicate on separate occasions
to ensure reproducibility. Survival was plotted by the Kaplan-
Meier analysis, and differences in percent survival were ana-
lyzed by the chi-square test. Differences in serum (133)--D-
glucan and the conidial equivalents were assessed for
significance using the Kruskal-Wallis test with Dunn’s test for
multiple comparisons. The Spearman rank correlation test was
used for correlations between serum (133)--D-glucan and
the conidial equivalents.
Serum (133)--D-glucan was detected early during the
course of infection, with significant increases in concentrations
by day 3 postinoculation (218 pg/ml, range of 49.2 to 609
pg/ml) compared to the thresholds of 60 pg/ml and 80 pg/ml set
by the manufacturer as the cutoffs for negative and positive
results in humans, respectively (Fungitell package insert; As-
sociates of Cape Cod), and to the negative controls (37.6 pg/
* Corresponding author. Mailing address: UTHSCSA, PERC MSC
6220, 7703 Floyd Curl Drive, San Antonio, TX 78229. Phone: (210)
567-8340. Fax: (210) 567-8328. E-mail: wiederholdn@uthscsa.edu.
 Published ahead of print on 26 December 2007.
1176
 o
n
 M
ay 11, 2015 by UNIV O
F TEXAS AUSTIN
http://aac.asm
.org/
D
ow
nloaded from
 
ml, range of 0 to 68.3 pg/ml, P 0.01) (Fig. 1). Increases in this
biomarker occurred 2 days prior to the first observed death in
infected mice. (133)--D-Glucan concentrations remained el-
evated on days 5 (635 pg/ml, range of 142 to 1,375 pg/ml) and
7 (442 pg/ml, range of 225 to 510 pg/ml) postinoculation.
Decreases in serum (133)--D-glucan were associated with
improved survival in animals treated with antifungal agents.
Posaconazole resulted in 100% survival and significant reduc-
tions in serum (133)--D-glucan concentrations in mice in-
fected with AF 293 (28.5 pg/ml) or CEA 10 (0 pg/ml) com-
pared to controls infected with AF 293 (758 pg/ml) or CEA 10
(707 pg/ml) (P  0.01) (Fig. 2). Although both amphotericin B
formulations resulted in improved survival against both iso-
lates (Fig. 2A and C), only liposomal amphotericin B signifi-
cantly reduced serum (133)--D-glucan concentrations (Fig.
2B and D), and neither formulation resulted in a median
concentration below 127 pg/ml. Posaconazole therapy also re-
sulted in significant reductions in conidial equivalents com-
pared to controls against both isolates (Table 1). However,
only liposomal amphotericin B treatment led to a reduction in
the pulmonary fungal burden and only against AF 293. Al-
though good correlation was found between (133)--D-glucan
and conidial equivalents for both isolates (AF 293, Spearman’s
rho, 0.81, P  0.0001; CEA 10 Spearman’s rho, 0.48, P 
0.0019), no treatment regimen completely sterilized lungs
when measured by conidial equivalents. This discrepancy be-
tween (133)--D-glucan serum concentrations and residual
lung tissue fungal burden may possibly reflect colonization
within the upper airways following pulmonary inoculation, as
previously described (1).
While the results of this study are promising, there are lim-
itations that must be considered. Although clinical studies have
shown the serum (133)--D-glucan assay to be a useful diag-
nostic marker for invasive fungal infections with a high nega-
tive predictive value (6, 7), it is not specific for Aspergillus
species, as (133)--D-glucan is a component of the cell wall of
a number of pathogenic fungi. In addition, one study reported
false positive reactions in patients with gram-positive or gram-
FIG. 1. Changes in serum (133)--D-glucan concentrations over
time in mice following pulmonary inoculation with A. fumigatus clinical
isolate AF 293. ‡, P 0.01 versus negative controls (Neg. Control) and
infected mice 1 h after inoculation (1 h SAC) and on day 1 postinocu-
lation. n  5 for each time point.
FIG. 2. Survival (A and C) of and serum (133)--D-glucan concentrations (B and C) in mice treated with antifungal agents following
pulmonary inoculation with A. fumigatus clinical isolate AF 293 (A and B) and CEA 10 (C and D). Treatment groups consisted of infected controls
(Infect. Control) (gray squares), 3 mg/kg amphotericin B deoxycholate (AMB) intraperitoneally QD (), 40 mg/kg posaconazole (POS) orally QD
(F), 10 mg/kg liposomal amphotericin B (LAMB) intravenously QD (), and uninfected controls (Neg. Control). ‡, P  0.01 versus infected
controls, AMB, and LAMB. , P  0.01 versus infected controls. n  10 per treatment group and infected controls.
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negative bacteremia (7). Several substances can also result in
false positives, including gauze exposed to serum, as well as
cellulose filters used in patients undergoing hemodialysis (Fun-
gitell package insert; Associates of Cape Cod). In addition, we
did not evaluate the effects of echinocandins on serum (133)-
-D-glucan concentrations.
These data suggest the potential use of the serum (133)--
D-glucan assay for the screening and early diagnosis of invasive
aspergillosis. Furthermore, the results from our model also sug-
gest that this assay may be useful for monitoring treatment effi-
cacy. Further clinical studies are warranted to confirm our results.
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TABLE 1. Pulmonary fungal burdens as measured by quantitative real-time PCR and reported as conidial equivalentsa
Treatment group
AF 293 CEA 10
Median log10 CE Range P value vs control Median log10 CE Range P value vs control
Control 10 9.1–11 9.6 0–11
POS 40 mg/kg 3.6 0–8.7 0.01 7.3 0–8.7 0.01
AMB 3 mg/kg 9.6 8.8–11 NS 9.0 7.6–10 NS
LAMB 10 mg/kg 8.9 8.3–9.8 0.01 9.5 7.7–10 NS
a CE, conidial equivalent; POS, posaconazole; AMB, amphotericin B deoxycholate; LAMB, liposomal amphotericin B, NS, not significant (P  0.05).
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